Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ITeos Therapeutics Inc shares valued at $525,967 were purchased by Detheux Michel on Jun 04 ’25. At $10.06 per share, Detheux Michel acquired 52,283 shares.
Also, DAVID L HALLAL purchased 38,227 shares, netting a total of over 384,782 in proceeds.
Before that, EcoR1 Capital, LLC had added 3,300,000 shares to its account. In a trade valued at $26,400,000, the 10% Owner bought ITeos Therapeutics Inc shares for $8.00 each. Upon closing the transaction, the insider’s holdings increased to 3,300,000 shares, worth approximately $109.03 million.
As published in a research note from Wells Fargo on May 28, 2025, ITeos Therapeutics Inc [ITOS] has been rated down from an Overweight to an Equal weight and the price target has been revised to $12. Analysts at Wedbush downgraded the stock from ‘”an Outperform”‘ to ‘”a Neutral”‘ outlook in a report released in late May. As of May 14, 2025, Leerink Partners has decreased its “an Outperform” rating to a “Market perform” for ITOS. Earlier on May 14, 2025, H.C. Wainwright downgraded its rating. Their new recommendation was “a Neutral” for ITOS stock which previously was a “a Buy”.
Analyzing ITOS Stock Performance
During the last five days, there has been a surge of approximately 1.39%. Over the course of the year, ITeos Therapeutics Inc shares have jumped approximately 32.81%. Shares of the company reached a 52-week high of $11.35 on 05/28/25 and a 52-week low of $4.80 on 04/09/25.
Support And Resistance Levels for ITeos Therapeutics Inc (ITOS)
According to the 24-hour chart, there is a support level at 10.06, which, if violated, would cause prices to drop to 9.91. In the upper region, resistance lies at 10.29. The next price resistance is at 10.37. RSI (Relative Strength Index) is 74.86 on the 14-day chart, showing overbought technical sentiment.
